RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ALX Oncology Holdings Stock

ALX Oncology Holdings ROCE 2024

ALX Oncology Holdings ROCE

-0.9

Ticker

ALXO

ISIN

US00166B1052

WKN

A2P79Z

In 2024, ALX Oncology Holdings's return on capital employed (ROCE) was -0.9, a 85.58% increase from the -0.48 ROCE in the previous year.

ALX Oncology Holdings Aktienanalyse

What does ALX Oncology Holdings do?

ALX Oncology Holdings Inc is a biopharmaceutical company specializing in the development and commercialization of immunotherapy products for the treatment of cancer. The company was founded in 2015 and is headquartered in Burlingame, California. It is listed on the NASDAQ stock exchange under the ticker symbol "ALXO." History ALX Oncology Holdings Inc was founded by Therese S. Wagner, a respected oncologist with extensive experience in cancer research. The company began its activities with a strong vision focused on developing targeted and effective treatments for cancer patients. Business Model ALX Oncology Holdings Inc is working on the development of immunotherapy products based on two mechanisms of action - inhibition of the CD47 molecule and activation of the myeloid cells of the immune system. The goal is to eliminate cancer cells by enabling them to be recognized and attacked by the immune system. This business model has the potential to improve both the effectiveness and versatility of cancer treatment. Divisions ALX Oncology Holdings Inc operates in several areas, including: Main products: • ALX148 - A monoclonal antibody that acts as a CD47 inhibitor • ALX148-Bispecifics - Two binding domains that contribute to the activation of the myeloid cells of the immune system In addition, ALX Oncology Holdings Inc collaborates with various partners to develop new drugs and therapies. These partnerships include both academic institutions and pharmaceutical companies. Products ALX148 is the flagship product of ALX Oncology. It is a monoclonal antibody that inhibits the CD47 molecule found on the surface of cancer cells, preventing their recognition by the immune system. By inhibiting CD47, the immune system can recognize and destroy cancer cells. ALX148-Bispecifics are antibody-drug conjugates (ADC) and bispecific antibodies (BsAb) that have been developed to activate the myeloid cells in the immune system by combining CD47 inhibitory capabilities with the activation of macrophage-associated ligands (CD40 and CD80). This results in a stronger immune response to cancer cells, leading to their destruction. Summary ALX Oncology Holdings Inc is a biotechnology company specializing in the development and commercialization of immunotherapy products for the treatment of cancer. Their products, ALX148 and ALX148-Bispecifics, inhibit the CD47 molecule and activate the immune system to fight cancer cells. The company collaborates with various partners and has the potential to provide new hope for people with cancer. ALX Oncology Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling ALX Oncology Holdings's Return on Capital Employed (ROCE)

ALX Oncology Holdings's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing ALX Oncology Holdings's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

ALX Oncology Holdings's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in ALX Oncology Holdings’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about ALX Oncology Holdings stock

What is the ROCE (Return on Capital Employed) of ALX Oncology Holdings this year?

The ROCE of ALX Oncology Holdings is -0.9 undefined this year.

How has the ROCE (Return on Capital Employed) of ALX Oncology Holdings developed compared to the previous year?

The ROCE of ALX Oncology Holdings has increased by 85.58% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of ALX Oncology Holdings?

A high Return on Capital Employed (ROCE) indicates that ALX Oncology Holdings has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of ALX Oncology Holdings?

A low ROCE (Return on Capital Employed) can indicate that ALX Oncology Holdings has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from ALX Oncology Holdings impact the company?

An increase in the ROCE of ALX Oncology Holdings can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of ALX Oncology Holdings affect the company?

A decrease in ROCE of ALX Oncology Holdings can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of ALX Oncology Holdings?

Some factors that can affect ALX Oncology Holdings's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of ALX Oncology Holdings so important for investors?

The ROCE of ALX Oncology Holdings is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can ALX Oncology Holdings take to improve the ROCE?

To improve the ROCE, ALX Oncology Holdings can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does ALX Oncology Holdings pay?

Over the past 12 months, ALX Oncology Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ALX Oncology Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of ALX Oncology Holdings?

The current dividend yield of ALX Oncology Holdings is .

When does ALX Oncology Holdings pay dividends?

ALX Oncology Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ALX Oncology Holdings?

ALX Oncology Holdings paid dividends every year for the past 0 years.

What is the dividend of ALX Oncology Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ALX Oncology Holdings located?

ALX Oncology Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von ALX Oncology Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ALX Oncology Holdings from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did ALX Oncology Holdings pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of ALX Oncology Holdings in the year 2023?

In the year 2023, ALX Oncology Holdings distributed 0 USD as dividends.

In which currency does ALX Oncology Holdings pay out the dividend?

The dividends of ALX Oncology Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ALX Oncology Holdings

Our stock analysis for ALX Oncology Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ALX Oncology Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.